- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01389661
Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H) (BIOMAX)
Regeneration of Maxillary Bone Cystic Cavities by Bio Implant of MSHV-H Cells Associated to a Cross-linked Serum Scaffold
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of this project is to provide a competitive clinical solution with an autologous product, a balanced cost and the possibility of extending use to other pathologies.
This protocol includes treatment of 10 patients with cystic disease of the jaws that meet all the inclusion criteria and none of the exclusion criteria.
For autologous cell preparation a sample of spongy bone from the maxillary tuberosity and 20 ml of serum are obtained from the patient in order to prepare the crosslinked protein matrix and the MSV-H cells. Cells are selected and expanded under GMP conditions according to the methodology used in previous trials (EudraCT 2005-005498-36, 2008-001191-68 and 2009-0170450-11 ). MSV-H cells are obtained directly from biopsy culture jawbone of the patient by cultivation techniques "in vitro" and differentiate for 21 days once conveyed in the matrix with osteogenic differentiation medium of the following composition: DMEM, 10% FBS, 1% P / E, 0.1 mM dexamethasone, 50 mM ascorbate 2-phosphate, 10 mM phosphate ßGlicerol. All differentiation factors have already been approved for clinical use. After the period of the product differentiation can be implanted to the patient.
The bioimplant is used to refill the bone defects after osteotomy and maxillary cyst enucleation, with 5-10 million cells per unit of 2 cm in diameter and 0.3 cm thick. The cavity is closed with the mucoperiosteal flap and sutured with reabsorbable material. The end point of the trial is to evaluate the feasibility, safety and indications of treatment efficacy according to both clinical criteria and objective imaging confirming the volumetric bone regeneration and maintenance over time. For this purposes orthopantomography exploration will be performed before and 2 and 6 months after intervention.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Malaga, Spain
- Bionand, Parque Tecnológico de Andalucía, Universidad de Málaga
-
Valladolid, Spain, 47003
- Instituto de Biologia y Genetica Molecular
-
-
Valladid
-
Valladolid, Valladid, Spain, 47012
- Rio Hortega University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Maxillar bone cyst with diameter larger than 2 cm and smaller than 4 cm
- Understanding and written acceptance of assay conditions
- Informed written consent of the patient for assay and for surgery
- In women, negative pregnancy test at t=0
- In women, compromise of using anticonceptive methods during the study
Exclusion Criteria:
- Age under 18 or over 65
- Incapacity or legal dependence
- Pregnancy, lactancy, or enrollment in fertility programs
- Previous or concomitant oncological processes.
- Positive serology for HIV-1 orHIV-2, Hepatitis B (HBsAg, Anti-HCV-Ab) or Hepatitis C (Anti-HCV-Ab).
- Immunocompromised patients
- Systemic disease with potential effects on bone metabolism
- Congenital or acquired maxillofacial malformation
- Patients with prescription of drugs acting on bone metabolism, suc as glucocorticoids and bisphosphonates
- Active or recent infection of the cyst
- Recidive of the cyst (previous surgery)
- Participation in other trials or studies in the last 3 months.
- Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MSV treatment
MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal
|
Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the feasibility and safety of the implementation of MSV in the treatment of maxillary cysts
Time Frame: up to 6 months
|
Clinical review and orthopantomograpy at different periods (0, 2 weeks, 2 months and 6 months) assessing evolution from baseline and possible complications.
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Indication of efficacy
Time Frame: up to 6 months
|
Imaging exploration to evaluate effectiveness through development of criteria for orthopantomography and bone-CT quantitative bone regeneration Evolution at 2 and 6 months from intervention will be assessed.
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Luis M Redondo, MD, PhD, Oral and Maxillofacial Surgeon, Río Hortega University Hospital, SACYL, Valladolid, Spain
- Study Director: Ana Sánchez, MD, PhD, Instituto de Biología y Genética Molecular (IBGM), University of Valladolid, Spain
- Study Director: Javier García-Sancho, MD, PhD, University of Valladolid, Spain
- Study Director: Jose Becerra, PhD, Centro Andaluz de Nanomedicina y Biotecnología (BIONAND), Universidad de Málaga, Ciber-bbn. Málaga, Spain.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TerCel0002
- 2010-024246-30 (EudraCT Number)
- EC10-255 (Other Grant/Funding Number: Spanish Ministry of Health, Programa de Terapias Avanzadas)
- BIOMAX-VA-2010 (Registry Identifier: Protocol Code)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Maxillary Cyst
-
University of Padova, School of Dental MedicineGeistlich Pharma AGCompleted
-
Cairo UniversityUnknown
-
Cairo UniversityUnknownOdontogenic Maxillary CystsEgypt
-
Cairo UniversityCompletedDental Implant | Maxillary Sinus | Maxillary Sinus Lift | Maxillary Sinus ElevationEgypt
-
Al-Azhar UniversityNot yet recruitingMaxillary Hypoplasia | Expansion of Maxillary Arch
-
Hatem Adel AboelhassanRecruitingOrbital Neoplasms | Zygomatic Fractures | Maxillary Neoplasms | Orbital Bone Fracture | Maxillary Cyst | Facial DeformityEgypt
-
Mashhad University of Medical SciencesCompletedDisorder of Maxillary Sinus | Maxillary Sinus Floor AugmentationIran, Islamic Republic of
-
University of PisaRecruitingMaxillary DeficiencyItaly
-
University of BaghdadNot yet recruitingMaxillary Expansion
-
University of GenovaUniversity of Milan; Università degli Studi di BresciaNot yet recruitingMaxillary Deficiency
Clinical Trials on MSV treatment
-
Red de Terapia CelularUniversity of Valladolid; Fundacion Teknon, Centro Medico Teknon, Barcelona; Centro... and other collaboratorsCompletedKnee Osteoarthritis | Osteoarthritis, Knee | Knee Degenerative DiseaseSpain
-
Instituto Universitario de Oftalmobiología Aplicada...University of ValladolidActive, not recruitingNon Arteritic Ischemic Optic NeuropathySpain
-
Red de Terapia CelularInstituto de Salud Carlos III; University of Valladolid; Centro en Red de Medicina...Withdrawn
-
Red de Terapia CelularCastilla-León Health Service; Instituto de Salud Carlos III; University of Valladolid and other collaboratorsCompletedCOVID-19 PneumoniaSpain
-
Red de Terapia CelularUniversity of Valladolid; Hospital del Río Hortega; Hospital Clínico Universitario... and other collaboratorsRecruitingLupus Nephritis | Lupus ErythematosusSpain
-
Red de Terapia CelularUniversity of Valladolid; CitospinCompletedLow Back Pain | Degenerative Disc Disease | Intervertebral Disc DiseaseSpain
-
Red de Terapia CelularCentro Medico Teknon; University of Valladolid; Sanidad de Castilla y LeónCompletedKnee Osteoarthritis | Osteoarthritis, Knee | Arthritis of KneeSpain
-
PfizerCompleted
-
PfizerCompleted
-
Chiesi Farmaceutici S.p.A.Completed